EXECUTIVE INTERVIEW – Emergent CDMO: A Molecule-to-Market Partner for Complex Biologics

09.01.2022

For nearly 25 years, Emergent has developed, manufactured, and delivered their own innovative vaccines and biotherapeutic products to combat public health threats and infectious diseases, thereby building a strong foundation of technical expertise in working with complex molecules and delivering them to the market.

Drawing on this fundamental experience, its CDMO business has supported the development and manufacturing of over 40 commercial and more than 100 clinical biologic programs for their biopharma partners.

Drug Development & Delivery recently interviewed Bill Hartzel, who joined the company in March 2022 as Senior Vice President and Head of CDMO Business, to discuss the company’s plans for current and future CDMO operations and client partnership opportunities.

Emergent CDMO

In The News

06.01.2020

Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...

03.19.2020

Novavax agreement for Experimental Vaccine Candidate for Coronavirus Disease

GAITHERSBURG, Md.,March 10, 2020(GLOBE NEWSWIRE) --Emergent BioSolutions Inc.(NYSE:EBS) announced today that it has entered...

03.19.2020

Vaxart AGREEMENT for Experimental Oral Vaccine Candidate for Coronavirus Disease

GAITHERSBURG, Md.,March 18, 2020(GLOBE NEWSWIRE) --Emergent BioSolutions Inc.(NYSE:EBS) announced today that it has entered...